Browse > Article
http://dx.doi.org/10.7314/APJCP.2014.15.24.10893

Prognostic Value of MGMT Promoter Methylation and TP53 Mutation in Glioblastomas Depends on IDH1 Mutation  

Wang, Kai (Department of Neuroradiology, Beijing Tian Tan Hospital, Capital Medical University)
Wang, Yin-Yan (Beijing Neurosurgical Institute)
Ma, Jun (Department of Neuroradiology, Beijing Tian Tan Hospital, Capital Medical University)
Wang, Jiang-Fei (Beijing Neurosurgical Institute)
Li, Shao-Wu (Department of Neuroradiology, Beijing Tian Tan Hospital, Capital Medical University)
Jiang, Tao (Beijing Neurosurgical Institute)
Dai, Jian-Ping (Department of Neuroradiology, Beijing Tian Tan Hospital, Capital Medical University)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.15, no.24, 2015 , pp. 10893-10898 More about this Journal
Abstract
Several molecular markers have been proposed as predictors of outcome in patients with glioblastomas. We investigated the prognostic significance of $O^6$-methylguanine-DNA methyltransferase (MGMT) promoter methylation and TP53 mutation status dependent on isocitrate dehydrogenase 1 (IDH1) mutation in glioblastoma patients. A cohort of 78 patients with histologically confirmed glioblastomas treated with radiation therapy and chemotherapy were reviewed retrospectively. We evaluated the prognostic value of MGMT promoter methylation and TP53 mutation status with regard to progression-free survival (PFS) and overall survival (OS). It was revealed that mutations in IDH1, promoter methylation of MGMT, TP53 mutation, age, Karnofsky performance status (KFS), and extension of resection were independent prognostic factors. In patients with an IDH1 mutation, those with an MGMT methylation were associated with longer PFS (p=0.016) and OS (p=0.013). Nevertheless, the presence of TP53 mutation could stratify the PFS and OS of patients with IDH1 wild type (p=0.003 and 0.029 respectively, log-rank). The MGMT promoter methylation and TP53 mutation were associated with a favorable outcome of patients with and without mutant IDH1, respectively. The results indicate that glioblastomas with MGMT methylation or TP53 mutations have improved survival that may be influenced by IDH1 mutation status.
Keywords
Glioblastomas; IDH1 mutation; MGMT promoter methylation; TP53 mutation; prognosis;
Citations & Related Records
Times Cited By KSCI : 2  (Citation Analysis)
연도 인용수 순위
1 Bello MJ, Alonso ME, Aminoso C, et al (2004). Hypermethylation of the DNA repair gene MGMT: association with TP53 G:C to A:T transitions in a series of 469 nervous system tumors. Mutat Res, 554, 23-32.   DOI
2 Bleeker FE, Atai NA, Lamba S, et al (2010). The prognostic IDH1( R132 ) mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma. Acta Neuropathol, 119, 487-94.   DOI
3 Butowski NA, Chang SM (2006). Glial tumors: the current state of scientific knowledge. Clin Neurosurg, 53, 106-13.
4 Carrillo JA, Lai A, Nghiemphu PL, et al (2012). Relationship between tumor enhancement, edema, IDH1 mutational status, MGMT promoter methylation, and survival in glioblastoma. Am J Neuroradiol, 33, 1349-55.   DOI
5 Dunn GP, Andronesi OC, Cahill DP (2013). From genomics to the clinic: biological and translational insights of mutant IDH1/2 in glioma. Neurosurg Focus, 34, 2.
6 Groenendijk FH, Taal W, Dubbink HJ, et al (2011). MGMT promoter hypermethylation is a frequent, early, and consistent event in astrocytoma progression, and not correlated with TP53 mutation. J Neurooncol, 101, 405-17.   DOI
7 Hartmann C, Hentschel B, Wick W, et al (2010). Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol, 120, 707-18.   DOI
8 Hegi ME, Diserens AC, Gorlia T, et al (2005). MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med, 352, 997-1003.   DOI
9 Jesien-Lewandowicz E, Jesionek-Kupnicka D, Zawlik I, et al (2009). High incidence of MGMT promoter methylation in primary glioblastomas without correlation with TP53 gene mutations. Cancer Genet Cytogenet, 188, 77-82.   DOI
10 Juratli TA, Kirsch M, Geiger K, et al (2012). The prognostic value of IDH mutations and MGMT promoter status in secondary high-grade gliomas. J Neurooncol, 110, 325-33.   DOI
11 Koca T, Basaran H, Sezen D, et al (2014). Comparison of linear accelerator and helical tomotherapy plans for glioblastoma multiforme patients. Asian Pac J Cancer Prev, 15, 7811-6.   DOI
12 Lee Y, Scheck AC, Cloughesy TF, et al (2008). Gene expression analysis of glioblastomas identifies the major molecular basis for the prognostic benefit of younger age. BMC Med Genomics, 1, 52.   DOI
13 Levidou G, El-Habr E, Saetta AA, et al (2010). P53 immunoexpression as a prognostic marker for human astrocytomas: a meta-analysis and review of the literature. J Neurooncol, 100, 363-71.   DOI
14 Li S, Jiang T, Li G, Wang Z (2008). Impact of p53 status to response of temozolomide in low MGMT expression glioblastomas: preliminary results. Neurol Res, 30, 567-70.   DOI
15 Minniti G, Salvati M, Arcella A, et al (2011). Correlation between O6-methylguanine-DNA methyltransferase and survival in elderly patients with glioblastoma treated with radiotherapy plus concomitant and adjuvant temozolomide. J Neurooncol, 102, 311-6.   DOI
16 Molenaar RJ, Verbaan D, Lamba S, et al (2014). The combination of IDH1 mutations and MGMT methylation status predicts survival in glioblastoma better than either IDH1 or MGMT alone. Neuro Oncol, 16, 1263-73.   DOI
17 Munoz DM, Guha A (2011). Mouse models to interrogate the implications of the differentiation status in the ontogeny of gliomas. Oncotarget, 2, 590-8.   DOI
18 Munoz DM, Tung T, Agnihotri S, et al (2013). Loss of p53 cooperates with K-ras activation to induce glioma formation in a region-independent manner. Glia, 61, 1862-72.   DOI
19 Nagy E, Gajjar KB, Patel, II, et al (2014). MGMT promoter hypermethylation and K-RAS, PTEN and TP53 mutations in tamoxifen-exposed and non-exposed endometrial cancer cases. Br J Cancer, 110, 2874-80.   DOI
20 Nobusawa S, Watanabe T, Kleihues P, Ohgaki H (2009). IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin Cancer Res, 15, 6002-7.   DOI   ScienceOn
21 Noushmehr H, Weisenberger DJ, Diefes K, et al (2010). Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell, 17, 510-22.   DOI   ScienceOn
22 Ohgaki H, Kleihues P (2007). Genetic pathways to primary and secondary glioblastoma. Am J Pathol, 170, 1445-53.   DOI
23 Ohgaki H, Kleihues P (2009). Genetic alterations and signaling pathways in the evolution of gliomas. Cancer Sci, 100, 2235-41.   DOI
24 Olson RA, Brastianos PK, Palma DA (2011). Prognostic and predictive value of epigenetic silencing of MGMT in patients with high grade gliomas: a systematic review and meta-analysis. J Neurooncol, 105, 325-35.   DOI
25 Parsons DW, Jones S, Zhang X, et al (2008). An integrated genomic analysis of human glioblastoma multiforme. Science, 321, 1807-12.   DOI   ScienceOn
26 Pashaki AS, Hamed EA, Mohamadian K, et al (2014). Efficacy of high dose radiotherapy in post-operative treatment of glioblastoma multiform-a single institution report. Asian Pac J Cancer Prev, 15, 2793-6.   DOI
27 Phillips HS, Kharbanda S, Chen R, et al (2006). Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell, 9, 157-73.   DOI
28 Sanson M, Marie Y, Paris S, et al (2009). Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol, 27, 4150-4.   DOI   ScienceOn
29 Sarmiento JM, Nuno M, Ortega A, et al (2014). Cystic glioblastoma: an evaluation of IDH1 status and prognosis. Neurosurgery, 74, 71-5: discussion 5-6.   DOI
30 Sathornsumetee S, Rich JN, Reardon DA (2007). Diagnosis and treatment of high-grade astrocytoma. Neurol Clin, 25, 1111-39.   DOI
31 SongTao Q, Lei Y, Si G, et al (2012). IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma. Cancer Sci, 103, 269-73.   DOI   ScienceOn
32 Soussi T, Wiman KG (2007). Shaping genetic alterations in human cancer: the p53 mutation paradigm. Cancer Cell, 12, 303-12.   DOI
33 Stancheva G, Goranova T, Laleva M, et al (2014). IDH1/IDH2 but not TP53 mutations predict prognosis in Bulgarian glioblastoma patients. Biomed Res Int, 2014, 654727.
34 Stander M, Peraud A, Leroch B, Kreth FW (2004). Prognostic impact of TP53 mutation status for adult patients with supratentorial World Health Organization Grade II astrocytoma or oligoastrocytoma: a long-term analysis. Cancer, 101, 1028-35.   DOI
35 Stupp R, Hegi ME, Mason WP, et al (2009). Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol, 10, 459-66.   DOI
36 Su Y, Yin L, Liu R, et al (2014). Promoter methylation status of MGMT, hMSH2, and hMLH1 and its relationship to corresponding protein expression and TP53 mutations in human esophageal squamous cell carcinoma. Med Oncol, 31, 784.   DOI   ScienceOn
37 Tabatabai G, Stupp R, van den Bent MJ, et al (2010). Molecular diagnostics of gliomas: the clinical perspective. Acta Neuropathol, 120, 585-92.   DOI
38 Turcan S, Rohle D, Goenka A, et al (2012). IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature, 483, 479-83.   DOI   ScienceOn
39 van den Bent MJ, Gravendeel LA, Gorlia T, et al (2011). A hypermethylated phenotype is a better predictor of survival than MGMT methylation in anaplastic oligodendroglial brain tumors: a report from EORTC study 26951. Clin Cancer Res, 17, 7148-55.   DOI
40 Verhaak RG, Hoadley KA, Purdom E, et al (2010). Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell, 17, 98-110.   DOI
41 Weller M, Felsberg J, Hartmann C, et al (2009). Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. J Clin Oncol, 27, 5743-50.   DOI
42 Wick W, Meisner C, Hentschel B, et al (2013). Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation. Neurology, 81, 1515-22.   DOI
43 Yan W, Zhang W, You G, et al (2012). Correlation of IDH1 mutation with clinicopathologic factors and prognosis in primary glioblastoma: a report of 118 patients from China. PLoS One, 7, 30339.   DOI